European Commission greenlights Mirati’s Krazati in KRAS-mutated NSCLC
Mirati filed a marketing authorisation application to the EMA for Krazati for patients within this indication in May 2022.
Mirati filed a marketing authorisation application to the EMA for Krazati for patients within this indication in May 2022.
What's Your Reaction?
